Generation of confluent cardiomyocyte monolayers derived from embryonic stem cells in suspension: a cell source for new therapies and screening strategies
Authors:
- M. BurgMBM. Burg
- E. WillboldEWE. Willbold
- H.F. AbtsHAH.F. Abts
- M. RuedigerMRM. Ruediger
- 1 January 2003
- journal article
- Published by Elsevier in Cytotherapy
- Vol. 5 (5) , 399-413
Abstract
Cellular cardiomyoplasty is evolving as a new strategy to treat cardiac diseases. A prerequisite is a reliable source of pure cardiomyocytes, which could also help in the exploitation of recent advances in genomics and drug screening. Our goal was to establish a robust lab-scale process for the generation of embryonic stem (ES)-cell-derived cardiomyocytes in suspension. A J1 ES cell clone carrying a construct consisting of the a-cardiac myosin heavy chain (αMHC) promoter driving the neomycin resistance gene was used for antibiotic-driven cardiomyocyte enrichment. Rotating suspension culture was established to initiate embryoid body (EB) formation. To track growth and differentiation kinetics, cell count and flow cytometry for SSEA-1, E-cadherin (stem-cell marker) and sarcomeric myosin (cardiomyocytes marker) was performed. Oct4 expression was measured via real time (RT)-PCR. Cultures comprising 2.5–8 × 106 differentiating ES cells/mL were obtained after 9 days in rotating suspension. Upon G418 addition, vigorous contracting spheres, termed cardiac bodies (CB), developed. These cultures consisted of about 2.1 × 105 enriched cardiomyocytes/ mL after 6—10 days of selection. Suspensions comprising 90—95% viable single cells were generated using an improved dissociation method. Seeding of cardiomyocytes with 7 × 104 cell/cm2 resulted in a homogeneous monolayer of synchronously contracting cells. Myocyte specific immunohistochemistry indicated purity of > 99%. We have established a reliable lab-scale protocol to generate cultures of highly enriched cardiomyocytes in suspension. This will facilitate development of larger-scale processes for stem-cell based cardiomyocyte supply. An improved method is provided to derive vital suspensions of cardiomyocytes, which could be utilized for transplantation as well as for drug screening purposes.Keywords
This publication has 52 references indexed in Scilit:
- Scalable Production of Embryonic Stem Cell-Derived CardiomyocytesTissue Engineering, 2003
- Stem cell pluripotency and transcription factor Oct4Cell Research, 2002
- High-Throughput Screening Strategies for Cardiac Ion ChannelsTrends in Cardiovascular Medicine, 2001
- High-throughput screeningNature Biotechnology, 1998
- HISTODIFFERENTIATION OF HAIR FOLLICLES IN GRAFTING OF CELL AGGREGATES OBTAINED BY ROTATION CULTURE OF EMBRYONIC RAT SKINScandinavian Journal of Plastic and Reconstructive Surgery and Hand Surgery, 1998
- Self Renewal of Embryonic Stem Cells in the Absence of Feeder Cells and Exogenous Leukaemia Inhibitory FactorGrowth Factors, 1997
- Cardiomyocyte Transfer into the Mammalian HeartAnnals of the New York Academy of Sciences, 1995
- Pancreatic Islet Cell Reaggregation SystemsPancreas, 1994
- Targeted mutation of the DNA methyltransferase gene results in embryonic lethalityCell, 1992
- Bioreactor for mammalian cell culture1989